T. Mix

Treatment of Secondary Hyperparathyroidism: Results of a Phase 2 Trial Evaluating an Intravenous Peptide Agonist of the Calcium-Sensing Receptor

R. Kewalramani, G. Block, D. Bushinsky, 2015, American Journal of Nephrology.

A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.

F. Locatelli, M. Chonchol, H. Abboud, 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial.

K. Mahaffey, D. Wheeler, G. London, 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials

G. Chertow, S. Moe, J. Cunningham, 2017, JAMA.

Ki-67 (clone MIB-1) proliferation index in recurrent glial neoplasms: no prognostic significance.

L. Recht, T. W. Smith, N. Litofsky, 1998, Surgical neurology.

Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.

K. Mahaffey, M. Jadoul, D. Wheeler, 2012, The New England journal of medicine.

A 57-year-old woman with gross hematuria and bilateral renal masses: an unusual presentation of acute interstitial nephritis.

T. Steinman, I. Stillman, T. Mix, 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Hospitalization during advancing chronic kidney disease.

A. Collins, W. S. St. Peter, J. Xue, 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Anemia: A Continuing Problem Following Kidney Transplantation

A. Kausz, B. Pereira, R. Ruthazer, 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease.

S. Solomon, M. Pfeffer, J. McMurray, 2005, American heart journal.